$LYRA
Lyra Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023266 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $11.00K $359.0K $14.00K
YoY Change -95.94% 2464.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.399M $5.137M $4.018M
YoY Change 23.32% 27.85% 51.62%
% of Gross Profit
Research & Development $9.451M $10.05M $7.077M
YoY Change -8.62% 41.98% 90.65%
% of Gross Profit
Depreciation & Amortization $222.0K $300.0K $400.0K
YoY Change -20.14% -25.0% 1112.12%
% of Gross Profit
Operating Expenses $13.85M $15.19M $11.10M
YoY Change -0.42% 36.86% 74.37%
Operating Profit -$14.83M -$11.08M
YoY Change 33.8% 74.15%
Interest Expense $933.0K $60.00K $26.00K
YoY Change 4342.86% 130.77% -13.33%
% of Operating Profit
Other Income/Expense, Net $60.00K $26.00K
YoY Change 130.77% -10.34%
Pretax Income -$14.22M -$14.77M -$11.06M
YoY Change 4.44% 33.57% 74.64%
Income Tax $13.00K
% Of Pretax Income
Net Earnings -$14.24M -$14.77M -$11.06M
YoY Change 4.54% 33.57% 74.53%
Net Earnings / Revenue -129409.09% -4113.09% -78964.29%
Basic Earnings Per Share -$0.40 -$0.85
Diluted Earnings Per Share -$0.39 -$0.40 -$850.3K
COMMON SHARES
Basic Shares Outstanding 31.83M 31.83M 13.00M
Diluted Shares Outstanding 36.83M 13.00M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.89M $109.6M $58.13M
YoY Change 113.99% 88.47% -28.73%
Cash & Equivalents $32.55M $109.6M $58.10M
Short-Term Investments $65.34M
Other Short-Term Assets $2.935M $2.672M $2.755M
YoY Change 35.19% -3.01% 37.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $100.8M $112.2M $60.89M
YoY Change 110.42% 84.33% -27.13%
LONG-TERM ASSETS
Property, Plant & Equipment $2.243M $3.753M $4.706M
YoY Change -50.19% -20.25% 413.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.281M $1.783M $574.0K
YoY Change 330.58% 210.63% 73.94%
Total Long-Term Assets $9.139M $7.233M $6.876M
YoY Change 31.52% 5.19% 82.15%
TOTAL ASSETS
Total Short-Term Assets $100.8M $112.2M $60.89M
Total Long-Term Assets $9.139M $7.233M $6.876M
Total Assets $110.0M $119.5M $67.76M
YoY Change 100.43% 76.3% -22.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.616M $2.900M $2.912M
YoY Change -16.29% -0.41% 449.43%
Accrued Expenses $10.58M $7.975M $5.020M
YoY Change 98.41% 58.86% 20.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.47M $13.61M $17.77M
YoY Change -20.69% -23.45% 277.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $14.74M $12.64M $2.801M
YoY Change 539.65% 351.12% 63.8%
Total Long-Term Liabilities $14.74M $12.64M $2.801M
YoY Change 539.65% 351.12% 63.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.47M $13.61M $17.77M
Total Long-Term Liabilities $14.74M $12.64M $2.801M
Total Liabilities $29.21M $26.24M $20.57M
YoY Change 42.15% 27.54% 220.67%
SHAREHOLDERS EQUITY
Retained Earnings -$248.7M -$234.4M -$179.8M
YoY Change 28.6% 30.37% 25.85%
Common Stock $329.4M $327.7M
YoY Change 44.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.75M $93.22M $47.19M
YoY Change
Total Liabilities & Shareholders Equity $110.0M $119.5M $67.76M
YoY Change 100.43% 76.3% -22.41%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$14.24M -$14.77M -$11.06M
YoY Change 4.54% 33.57% 74.53%
Depreciation, Depletion And Amortization $222.0K $300.0K $400.0K
YoY Change -20.14% -25.0% 1112.12%
Cash From Operating Activities -$12.16M -$10.85M -$10.31M
YoY Change 7.67% 5.16% 172.86%
INVESTING ACTIVITIES
Capital Expenditures $28.00K -$29.00K -$517.0K
YoY Change -102.59% -94.39% -10.86%
Acquisitions
YoY Change
Other Investing Activities -$64.84M
YoY Change
Cash From Investing Activities -$64.87M -$29.00K -$517.0K
YoY Change 5889.84% -94.39% -10.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -236.0K -84.00K
YoY Change -100.0% 180.95% -87.46%
NET CHANGE
Cash From Operating Activities -12.16M -10.85M -10.31M
Cash From Investing Activities -64.87M -29.00K -517.0K
Cash From Financing Activities 0.000 -236.0K -84.00K
Net Change In Cash -77.03M -11.11M -10.92M
YoY Change 522.04% 1.8% 117.0%
FREE CASH FLOW
Cash From Operating Activities -$12.16M -$10.85M -$10.31M
Capital Expenditures $28.00K -$29.00K -$517.0K
Free Cash Flow -$12.19M -$10.82M -$9.797M
YoY Change 19.37% 10.41% 206.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47918000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4503000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
608000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1355000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1089000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
329000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1783000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
762000
CY2022Q3 us-gaap Assets
Assets
119463000
CY2021Q4 us-gaap Assets
Assets
54867000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2900000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3125000
CY2022Q3 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7321000
us-gaap Operating Expenses
OperatingExpenses
42503000
CY2021Q4 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4258000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
654000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1074000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
15185000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
11095000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2730000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9789000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13605000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18246000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12633000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1926000
CY2021Q4 us-gaap Liabilities
Liabilities
20551000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001327273
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39273
dei Entity Registrant Name
EntityRegistrantName
Lyra Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1700838
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
393-4600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
LYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31827008
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31827008
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13007178
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13007178
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
32000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
327630000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227700000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234440000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193397000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
93222000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
34316000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119463000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54867000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
359000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31827008
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109558000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45747000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
329000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2343000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2171000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
112230000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1352000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10048000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7077000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29346000
CY2022Q3 us-gaap Liabilities
Liabilities
26241000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19352000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5137000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4018000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13157000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10639000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
844000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11911000
us-gaap Operating Expenses
OperatingExpenses
29991000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14826000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11081000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41151000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29977000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Investment Income Interest
InvestmentIncomeInterest
108000
us-gaap Investment Income Interest
InvestmentIncomeInterest
81000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
60000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
81000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14766000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11055000
us-gaap Net Income Loss
NetIncomeLoss
-41043000
us-gaap Net Income Loss
NetIncomeLoss
-29896000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14766000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11055000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41043000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29896000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.30
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36826364
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36826364
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13001514
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13001514
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28014434
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28014434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12979837
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12979837
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74492000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
262000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7802000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
67551000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
331000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
656000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11039000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
23257000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4244000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
57499000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
733000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11055000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47188000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
34316000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
us-gaap Net Income Loss
NetIncomeLoss
-41000000.0
us-gaap Net Income Loss
NetIncomeLoss
-29900000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234400000
CY2022Q2 lyra Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
96251000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1107000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14366000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
106249000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1739000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14766000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
93222000
us-gaap Profit Loss
ProfitLoss
-41043000
us-gaap Profit Loss
ProfitLoss
-29896000
us-gaap Share Based Compensation
ShareBasedCompensation
3690000
us-gaap Share Based Compensation
ShareBasedCompensation
1988000
us-gaap Depreciation
Depreciation
845000
us-gaap Depreciation
Depreciation
723000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
172000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1431000
lyra Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-747000
lyra Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-705000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
787000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-167000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1167000
lyra Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2814000
lyra Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
966000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-796000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-731000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3648000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
11986000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14523000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2302000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2302000
lyra Proceeds From Sale Of Common Stock And Pre Funded Warrant Net
ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet
100495000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4246000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
241000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
604000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96257000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
363000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
64900000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16462000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46076000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74922000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110976000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58460000
lyra Other Assets Included In Accrued Expenses
OtherAssetsIncludedInAccruedExpenses
249000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1049000
lyra Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
4000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-21
lyra Cash Provided By Financing Activities
CashProvidedByFinancingActivities
350400000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
162100000
lyra Proceeds From Government Contracts
ProceedsFromGovernmentContracts
16800000
lyra Proceeds From License And Collaboration Agreement
ProceedsFromLicenseAndCollaborationAgreement
17000000.0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109600000
CY2020Q1 lyra Number Of Patients
NumberOfPatients
67
CY2021Q4 lyra Employer Side Social Security Payments Due Percentage
EmployerSideSocialSecurityPaymentsDuePercentage
0.50
CY2022Q4 lyra Employer Side Social Security Payments Due Percentage
EmployerSideSocialSecurityPaymentsDuePercentage
0.50
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1400000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4371682
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1850313
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2021Q3 us-gaap Alternative Investment Change In Valuation Technique
AlternativeInvestmentChangeInValuationTechnique
false
CY2022Q3 us-gaap Alternative Investment Change In Valuation Technique
AlternativeInvestmentChangeInValuationTechnique
false
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8477000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8382000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4724000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3879000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4503000
CY2022Q3 us-gaap Depreciation
Depreciation
300000
CY2021Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
700000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3082000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2429000
CY2022Q3 lyra Third Party Research And Development Expenses Current
ThirdPartyResearchAndDevelopmentExpensesCurrent
3055000
CY2021Q4 lyra Third Party Research And Development Expenses Current
ThirdPartyResearchAndDevelopmentExpensesCurrent
1196000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
885000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
486000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
299000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
147000
CY2022Q3 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7321000
CY2021Q4 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4258000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of common stock are entitled to one vote for each share held.
lyra Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1
CY2021Q2 lyra Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants
StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants
250000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.850
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10939461
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1739000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
733000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3690000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1988000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11341000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.026
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.852
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.842
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.814
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
45483
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
8112
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.78
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
35418
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.78
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1662861
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.34
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
918000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2765174
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.21
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2718
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89053
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.29
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4336264
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1917000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1245916
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1102000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4336264
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1917000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.47
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.84
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
21000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
264000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1134000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1121000
CY2022Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
one additional 5-year term
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
264000
us-gaap Operating Lease Cost
OperatingLeaseCost
792000
us-gaap Operating Lease Cost
OperatingLeaseCost
792000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
870000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
857000
us-gaap Variable Lease Cost
VariableLeaseCost
3744000
us-gaap Variable Lease Cost
VariableLeaseCost
2219000
us-gaap Lease Cost
LeaseCost
4536000
us-gaap Lease Cost
LeaseCost
3011000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
285000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
382000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
669000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
657000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
654000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2021Q2 lyra Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization
FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization
135000000.0
CY2022Q3 lyra Combined Performance Obligation
CombinedPerformanceObligation
8300000
CY2022Q3 lyra Development Activities Performance Obligation
DevelopmentActivitiesPerformanceObligation
3700000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
11715000
lyra Development Milestone Achieved
DevelopmentMilestoneAchieved
5000000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1352000
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
15363000
CY2022Q3 lyra Revenue Recognition Material Impact Due To Amendment
RevenueRecognitionMaterialImpactDueToAmendment
0
lyra Revenue Recognition Material Impact Due To Amendment
RevenueRecognitionMaterialImpactDueToAmendment
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-22-023266-index-headers.html Edgar Link pending
0000950170-22-023266-index.html Edgar Link pending
0000950170-22-023266.txt Edgar Link pending
0000950170-22-023266-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lyra-20220930.htm Edgar Link pending
lyra-20220930.xsd Edgar Link pending
lyra-ex10_1.htm Edgar Link pending
lyra-ex10_2.htm Edgar Link pending
lyra-ex31_1.htm Edgar Link pending
lyra-ex31_2.htm Edgar Link pending
lyra-ex32_1.htm Edgar Link pending
lyra-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
lyra-20220930_cal.xml Edgar Link unprocessable
lyra-20220930_def.xml Edgar Link unprocessable
lyra-20220930_lab.xml Edgar Link unprocessable
lyra-20220930_pre.xml Edgar Link unprocessable
lyra-20220930_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending